2022年6月3日到7日，美国临床肿瘤学会(ASCO)2022年会将在美国芝加哥以线上线下形式举办。根据摘要显示，中国药企入选了上百个临床试验，涉及靶点种类除了上榜数量最多的老靶点“PD-1/L1、HER2、VEGFR、EGFR、BTK”外，一些新靶点也映入眼帘。（摘要链接：https://meetings.asco.org/meetings/2022-asco-annual-meeti...
官网链接 https://meetings.asco.org/meetings/2022-asco-annual-meeting/288/program-guide/scheduled-sessions
2022年6月3日到7日,美国临床肿瘤学会(ASCO)2022年会将在美国芝加哥以线上线下形式举办。根据摘要显示,中国药企入选了上百个临床试验,涉及靶点种类除了上榜数量最多的老靶点“PD-1/L1、HER2、VEGFR、EGFR、BTK”外,一些新靶点也映入眼帘。 (摘要链接:https://meetings.asco.org/meetings/2022-asco-annual-meeting/...
[1]2022年美国临床肿瘤学会(ASCO)年会 https://meetings.asco.org/meetings/2022-asco-annual-meeting/288/program-guide/scheduled-sessions [2]PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | NEJM h...
Exhibition Stands in ASCO Annual Meeting Hostesses in ASCO Annual Meeting Report an error ASCO Annual Meeting: the trade show The American Society of Clinical Oncology (ASCO) Annual Meeting is the premier educational and scientific event in the oncology community, highlighting the most advanced ...
A multitudeof presentations were available to attendees at the 2022 ASCO Annual Meeting, including hundreds in the hematologic malignancies tracks. In addition to coverage inThe ASCO Postof the major news stories at the meeting, here we offer summaries of additional studies of special interest... ...
company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that preliminary results of Catumaxomab for advanced Gastric Cancer (GC) with peritoneal metastasis is published online at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting....
Agree to present the abstract if it is selected for presentation at the ASCO Annual Meeting. (This includes being present during the scheduled time of a poster session.) If the first author is employed by a company as defined by the CMSS Code for Interactions with Companies (see Submission ...
The 2024 ASCO Annual Meeting features the latest research news and policy updates across oncology. We report on the top clinical trial findings and gather expert insights about how the new evidence may change clinical practice.
Michael Bailey, president and chief executive officer of AVEO, stated, “We are pleased to present these three posters at this year’s ASCO Annual Meeting, which we believe further showcase the profile of tivozanib as an effective therapy for relapsed or refractory advanced (R/R) renal c...